The Impact of CFTR Modulator Triple Therapy on Type 2 Inflammatory Response in Patients with Cystic Fibrosis

BACKGROUND: Treatment of cystic fibrosis (CF) has been revolutionized by the use of cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators such as elexacaftor/tezacaftor/ivacaftor (ETI) triple therapy. Prior studies support a role for type 2 (T2) inflammation in many people wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Ajay, Lee, Irene, Li, Galvin, Jones, Marieke, Hanson, Lydia, Lonabaugh, Kevin, List, Rhonda, Borish, Larry, Albon, Dana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197784/
https://www.ncbi.nlm.nih.gov/pubmed/37215020
http://dx.doi.org/10.21203/rs.3.rs-2846739/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197784/
https://www.ncbi.nlm.nih.gov/pubmed/37215020
http://dx.doi.org/10.21203/rs.3.rs-2846739/v1

Ejemplares similares